ESB1609

ESB1609 is an orally administered, brain-penetrant, small-molecule agonist of the sphingosine-1-phosphate receptor 5 (S1P5) being developed for neurodegenerative and lysosomal storage disorders, particularly Niemann-Pick disease type C and other CNS lysosomal storage diseases.[2][3][5] It is a highly selective S1P5 receptor agonist with sub-100 nM potency and >700-fold selectivity over other S1P receptor subtypes, designed to restore CNS lipid homeostasis by promoting cytosolic egress of sphingosine-1-phosphate and thereby reducing abnormal ceramide and cholesterol accumulation.[1][2][5] In Phase 1 single- and multiple-ascending-dose studies in healthy volunteers, ESB1609 demonstrated linear pharmacokinetics, CNS penetration (measurable in cerebrospinal fluid), and a favorable safety and tolerability profile at exposures anticipated to be therapeutically relevant, supporting further development as a first-in-class S1P5 pathway–based therapy for genetically defined neurodegenerative diseases.[2][3][5]